We are very pleased to announce that Dr. David Gould will be joining the Burke Neurological Institute (BNI) as Chief Operating Officer starting in early April.
As we look back, our news highlights during the pandemic year of 2020 spotlight how we joined together to overcome challenges to carry on with our mission to find cures for chronic neurological disabilities.
Benfotiamine and Cognitive Decline in Alzheimer's Disease, a small exploratory clinical trial, conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute is listed in CNN Health’s article on ”Top 2020 health stories you may have missed because of Covid-19” under Advances in Alzheimer’s.
A small exploratory clinical trial conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute in collaboration with physicians at the Burke Rehabilitation Hospital, suggests that Benfotiamine is safe and potentially efficacious in improving cognitive outcomes among people living with Mild Cognitive Impairment and mild Alzheimer’s disease (AD).
Very recently, the Prusky Lab has resumed limited clinical studies on children at Blythedale Children’s Hospital and adults at Burke Neurological Institute. “I am most proud of lab member’s ability to adapt to the peculiar circumstances they have found themselves in, and make outstanding progress.,” shared Dr. Glen Prusky.
